缬沙坦治疗69例心力衰竭的临床分析

目的探讨缬沙坦对慢性心力衰竭(CHF)的疗效和安全性.方法69例经常规洋地黄、利尿剂,血管扩张剂,血管紧张素转换酶抑制剂(ACEI)类药物治疗效果欠佳的临床诊断为慢性心力衰竭患者,随机分为A、B组2组:即A组(35例,对照组,常规治疗);B组(34例,常规治疗加缬沙坦80mg/qd)疗程6个月,观察各组病人治疗疗效,治疗前后各组心率、血压、心功能参数即左室射血分数(LVEF)及二尖瓣血流峰速E/A比值的变化.结果治疗后B组同常规治疗组比较,心率、血压与治疗前比较均明显改善(P＜0.05),LVEF增加(P＜0.05),E/A比值增加(P＜0.05),临床心功能改善1～2级.药物副作用少,患者耐受性好.结论缬沙坦治疗慢性心力衰竭的疗效显著,比常规治疗的疗效显著,安全可靠.

The clinical analysis on 69 patients with chronic heart failure and cardiac dysfunction

Objective To investigate the effect of valartan in treating chronic heart failure and cardiac dysfunction. Methods 69 cases hypertension patients with chronic heart failure and cardiac dysfunctions were randomly divided into two groups: valartan group(34 cases): Valartan 80 mg/d was given to the patients; conventionality therapy group with used drugs of cardicglycoside, diuresis and angiotens inconverting enzyme inhibitor medicine(35 cases). The parameters of LV end-diastolic diameter (LVDd), end-diastolic septal thickness (IVSTd), LV end-diastolic posterior wall thickness (LVPWTd), LV mass index (LVMi), LV ejection fraction (EF), isovolumic relaxation time(IRT), mitral valve diastolic E and A maximum velocity (E end A peak), ratio of E/A were measured before and after the treatment. blood lipid and glucose were monitored before and after the treatment. Results After 6 months of treatment, the parameters of LVH (LVDd, IVSTd, LVPWd LVMi) and cardiac function parameters (E/A, IRT and EF) were all improved in both of valartan group and conventionality therapy groups (P<0.01). LVDd, IVSTd, LVPWd, LVMi, IRT were decreased, E/A and EF were increased accordingly. After 12 months of treatment and follow-up, parameters of LVH and cardiac function markedly reversed in valartan group than that in conventionality therapy group. Conclusions Valartan was remarkable effect in treating hypertension with left chronic heart failure and cardiac dysfunction.